Rocuronium
15
1
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
40%
6 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
General Anesthesia With and Without Muscle Relaxation and Muscle Strength Recovery
Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation
Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation
Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety
Peribulbar Rocuronium in Adult Strabismus Surgery
Comparison of Standard rapi̇d Sequential Intubation Protocol With Rocuronium in Emergency Department
Lean Body Weight-adjusted Rocuronium Dose and Intubation Conditions
Relationship Between Effect Duration of Rocuronium and Body Composition Analysis Data.
Rapid Sequence Intubation With Rocuronium in Elderly Patients
Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium
Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine
Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex
Continuous Infusion and Bolus Doses of Rocuronium During Lumbal Discectomy, Muscle Strength and Patient Recovery
Effect of Pre-treatment With Magnesium Sulfate on the Duration of Deep Neuromuscular Blockade With Rocuronium
Effect of Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea